Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 2—February 2017

Determination of Elizabethkingia Diversity by MALDI-TOF Mass Spectrometry and Whole-Genome Sequencing

Helle Brander EriksenComments to Author , Heidi Gumpert, Cecilie Haase Faurholt, and Henrik Westh
Author affiliations: Copenhagen University Hospital, Hvidovre, Denmark (H.B. Eriksen, H. Gumpert, H. Westh); Copenhagen University Hospital, Frederiksberg, Denmark (C.H. Faurholt); University of Copenhagen, Copenhagen, Denmark (H. Westh)

Main Article


Antimicrobial susceptibility of Elizabethkingia isolate HvH-WGS333 from patient with hospital-acquired septic arthritis, Copenhagen, Denmark 2015*

Antimicrobial MIC, mg/L MIC breakpoint, S≤/R>, mg/L Interpretation
Ciprofloxacin 0.25 0.5/1 Susceptible
Co-trimoxazole 0.125 4/4 Susceptible
Tigecycline 0.5 0.25/0.5 Intermediate
Piperacillin/tazobactam† 16 4/16 Intermediate
Amoxicillin/clavulanic acid‡ 8 2/8 Intermediate
Ampicillin >256 2/8 Resistant
Cefuroxime >256 4/8 Resistant
Ceftazidime >256 4/8 Resistant
Meropenem >32 2/8 Resistant
Gentamicin 12 4/4 Resistant
Colistin >256 4/4 Resistant

*Submitted isolate to GenBank (accession no. NZ_MCJF00000000.1). The isolate contains antimicrobial resistance genes blaB-4, blaGOB-13, and an extended-spectrum β-lactamase, sharing 90.6% nucleotide identity to blaCME-1. Antimicrobial susceptibility testing was performed by using Etest (bioMérieux, Marcy l’Etoile, France) according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines ( For interpretation, non–species-related (pharmacokinetics/pharmacodynamics) breakpoints were used except for co-trimoxazole, in which Stenotrophomonas malthophilia breakpoints were used, and for gentamicin and colistin, in which Pseudomonas sp. breakpoints were used. R, resistance; S, susceptibility.
†For susceptibility testing purposes, the concentration of tazobactam was fixed at 4 mg/L.
‡For susceptibility testing purposes, the concentration of clavulanic acid was fixed at 2 mg/L.

Main Article

Page created: January 17, 2017
Page updated: January 17, 2017
Page reviewed: January 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.